Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02958150
Other study ID # DEX-PCH-VMNI
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date October 2016
Est. completion date October 2022

Study information

Verified date March 2022
Source Basque Health Service
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compare the effectiveness of dexmedetomidine as a sedative drug during NIV and the different strategies routinely used in patients with ARF of different aetiologies. Efficacy will be assessed based on absence of intubation, short term prognosis, and occurrence of medical complications.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date October 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over 18 years of age. - Competent or with legal representative able to sign inform consent. - Reversible ARF secondary to heart failure, COPD exacerbation, pneumonia, or at risk of pot-extubation failure* who meet the criteria for starting NIV. - Signs and symptoms of respiratory distress or - Moderate to severe dyspnoea, grater than usual and/or - Respiratory rate greater than 25 in COPD or greater than 30 in hypoxemic ARF and/or - Use of accessory muscles and/or paradoxical breathing and/or - Hypercapnic encephalopathy - And changes in gas exchange - PaCO2>45 mmHg, pH<7.35 and/or - PaO2/FiO2 between 300 and 150. *Patients at risk of post-extubation failure: Patients who meet at least one of the following criteria. - Impaired consciousness. - Age over 65 years - Heart failure with EF >30% - Severe disease with an Acute Physiology and Chronic Health Evaluation (APSCHE) score >12. - Protracted weaning before extubation Exclusion Criteria: - Respiratory arrest, direct indication of OTI and IMV. - Severe unstable comorbidity (myocardial ischemia with ejection fraction <30%, arrythmia, uncontrolled hypotension defined as systolic blood pressure less than 90 mmHg with doses of norepinephrine>0.5 mcg/kg/min and/or dobutamine>10 mcg/kg/min). - Inability to protect the airway: bronchial aspiration. - Fixed upper airway obstruction. - Tracheostomy. - Undrained pneumothorax. - Severe agitation or lack of collaboration of the patient despite medication administered. - Facial burns or trauma. - Facial surgery or anatomical changes which prevent mask fitting. - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Allergy to eggs, soya, or peanuts. - HR< 50 bpm not induced by beta- blockers. - Advanced heart block (grade 2 or 3) unless paced. - Acute cerebrovascular conditions. - Increased intracranial pressure. - Closed angle glaucoma. - Myasthenia gravis. - Concurrent use of CYP3A4 inhibitors (amprenavir, atazanavir, or ritonavir). - Refuse to participate in the trial. - Pregnant or nursing patients.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexmedetomidine

Procedure:
Standard Clinical Practice


Locations

Country Name City State
Spain Araba University Hospital Vitoria Álava

Sponsors (1)

Lead Sponsor Collaborator
Basque Health Service

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determinate the percentage of orotracheal intubations, and thus the need for NIV during the trial. Need for intubation is defined as the presence of any of the following: SpO2<80% or P aO2/FiO2<150, seizures, poor secretion management, hypercapnia and pH<7.20, hypotension: systolic blood pressure (SBP)<80 mmHg refractory despite administration of vasoactive amines or electrocardiogram (ECG) with ischaemic changes or ventricular arrhythmia resulting from myocardial hypoxia. 72 hours
Secondary To determinate NIV duration of NIV in each group. Number of hours the patient will be on NIV. 72 hours
Secondary To analyse stay at the ICU in each group. Number of days patients stay at the ICU until they are discharged home or die. An average of 5 days
Secondary To analyse hospital stay in each group Number of days patients remain at the hospital until they are discharged home or die. 15 days
Secondary To compare all-cause mortality at the ICU in both groups. Percentage of all deaths from any cause in patients with ARF on NIV at the ICU in both study groups. Through study completion, an average of 3 years
Secondary To compare specific mortality at the ICU in both groups. Percentage of deaths attributable to ARF in patients on NIV at the ICU in both study groups. Through study completion, an average of 3 years
Secondary To analyse hospital-specific mortality. Percentage of all deaths attributable to ARF in patients on NIV at the ICU discharged to a ward in the 2 study groups. Through study completion, an average of 3 years
Secondary To analyse all-cause hospital mortality. Percentage of all deaths from any aetiology of ARF in patients treated with NIV in the ICU discharged to a ward in the 2 study groups. Through study completion, an average of 3 years
Secondary To report the course of ARF in each group. Based on the presence before the start of NIV 1 and 24 hours after NIV
Secondary To report NIV tolerance during administration of dexmedetomidine versus SCP. Nausea and/or vomiting, Aspiration pneumonia, delirium, agitation, interface tolerance or pain secondary to use of interface. During administration of dexmedetomidine/SCP and up to 24 hours after drug infusion/SCP is completed.
Secondary To report the adverse effects of dexmedetomidine. Bradycardia, hypotension, tachycardia, hypertension and/or transient respiratory depression. During drug administration and up to 24 hours after drug infusion is completed.
Secondary To asses patient satisfaction with dexmedetomidine as compared to SCP Patient satisfaction with use of dexmedetomidine as compared to drugs used in SCP will be estimated once NIV and dexmedetomidine/SCP infusion have been completed, using a Likert type questionnaire. Through study completion, an average of 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05144633 - Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Recruiting NCT03021902 - Nutrition and Exercise in Critical Illness Phase 2
Completed NCT02902146 - Bougie Use in Emergency Airway Management N/A
Completed NCT02901158 - Esophageal Manometry in Mechanically Ventilated Patients
Completed NCT02236559 - High Flow Therapy for the Treatment of Respiratory Failure in the ED N/A
Recruiting NCT02056093 - Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist N/A
Terminated NCT01083277 - Variable Ventilation During Acute Respiratory Failure N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01462279 - Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness N/A
Completed NCT01114022 - Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane N/A
Active, not recruiting NCT01058421 - Treatment of Critical Illness Polyneuromyopathy Phase 2
Completed NCT00252616 - Timing of Target Enteral Feeding in the Mechanically Ventilated Patient Phase 2/Phase 3
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT06051292 - Decremental Esophageal Catheter Filling Volume Titration For Transpulmonary Pressure Measurement N/A
Completed NCT04601090 - Survival Rates and Longterm Outcomes After COVID-19
Recruiting NCT05423301 - Global Physiotherapy in ICU Patients With High Risk Extubation Failure N/A
Completed NCT02447692 - Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study N/A
Completed NCT04016480 - HFNC During Bronchoscopy for Bronchoalveolar Lavage N/A
Completed NCT04507425 - High Flow Nasal Cannula With Noninvasive Ventilation N/A